246 related articles for article (PubMed ID: 31468649)
1. Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes.
Langford BE; Evans M; Haskins-Coulter T; O'Connor M; Cant HEO; Eddowes LA; Edmonds C; Tank A
Diabetes Obes Metab; 2020 Jan; 22(1):39-50. PubMed ID: 31468649
[TBL] [Abstract][Full Text] [Related]
2. Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
Kim YJ; Hwang SD; Lim S
Front Endocrinol (Lausanne); 2020; 11():553. PubMed ID: 32973680
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
Kanters S; Wilkinson L; Vrazic H; Sharma R; Lopes S; Popoff E; Druyts E
BMJ Open; 2019 Jul; 9(7):e023458. PubMed ID: 31340953
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
Sharma R; Wilkinson L; Vrazic H; Popoff E; Lopes S; Kanters S; Druyts E
Curr Med Res Opin; 2018 Sep; 34(9):1595-1603. PubMed ID: 29764222
[TBL] [Abstract][Full Text] [Related]
5. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
Patel K; Carbone A
Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
[No Abstract] [Full Text] [Related]
6. Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis.
McNeill AM; Davies G; Kruger E; Kowal S; Reason T; Ejzykowicz F; Hannachi H; Cater N; McLeod E
Diabetes Ther; 2019 Apr; 10(2):473-491. PubMed ID: 30689140
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.
Avgerinos I; Manolopoulos A; Michailidis T; Kitsios K; Liakos A; Karagiannis T; Dimitrakopoulos K; Matthews DR; Tsapas A; Bekiari E
Diabetes Obes Metab; 2021 Mar; 23(3):822-831. PubMed ID: 33300282
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
[TBL] [Abstract][Full Text] [Related]
9. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S
Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900
[TBL] [Abstract][Full Text] [Related]
10. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Shyangdan DS; Uthman OA; Waugh N
BMJ Open; 2016 Feb; 6(2):e009417. PubMed ID: 26911584
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Boeder S; Edelman SV
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):62-77. PubMed ID: 31081593
[TBL] [Abstract][Full Text] [Related]
12. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
13. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
[TBL] [Abstract][Full Text] [Related]
14. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Chen L; Xue Q; Yan C; Tang B; Wang L; Zhang B; Zhao Q
Front Endocrinol (Lausanne); 2023; 14():1256548. PubMed ID: 38027214
[TBL] [Abstract][Full Text] [Related]
15. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Lu J; Tang L; Meng H; Zhao J; Liang Y
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Musso G; Gambino R; Cassader M; Paschetta E
BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
[TBL] [Abstract][Full Text] [Related]
17. Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors.
Willis M; Asseburg C; Neslusan C
Diabetes Res Clin Pract; 2019 Feb; 148():222-233. PubMed ID: 30641163
[TBL] [Abstract][Full Text] [Related]
18. Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.
Elian V; Popovici V; Karampelas O; Pircalabioru GG; Radulian G; Musat M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396657
[TBL] [Abstract][Full Text] [Related]
19. [Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor.
Merész G; Szabó S; Dóczy V; Hölgyesi Á; Szakács Z
Orv Hetil; 2020 Mar; 161(13):491-501. PubMed ID: 32202151
[TBL] [Abstract][Full Text] [Related]
20. The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for metformin: a systematic review and meta-analysis of randomized controlled trials.
Li X; Zhang Q; Zhou X; Guo S; Jiang S; Zhang Y; Zhang R; Dong J; Liao L
Aging (Albany NY); 2021 May; 13(9):12748-12765. PubMed ID: 33973870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
